EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseOpen Access · CC BY-NC-SA 4.0

Comparing the Efficacy and Safety of Different Varenicline Dosing Strategies for First-Line Cigarette Smoking Cessation: A Network Meta-Analysis

Samuel Partogi Nababan, Gresita Novelia Uirianto, Juan Fransiscus Wira, Whitney Joycelyn Tenaya, Deva Fitra Firdausa Anwar

Journal of Asian Medical Students' Association · 28.04.2026

DOI: 10.52629/jamsa.vi.869 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Journal of Asian Medical Students' Association, online erschienen am 28.04.2026. Verfasst von Samuel Partogi Nababan und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Tobacco use causes more than eight million deaths annually, requiring effective cessation strategies. Varenicline is a highly effective smoking cessation pharmacotherapy, but optimal dosing strategies remain debated. This network meta-analysis compares the efficacy and safety of alternative varenicline regimens (e.g., standard, extended duration, flexible dosing) to guide personalised treatment.

Method

Literature search was conducted across seven databases up to February 17, 2025. Quality appraisal was performed with the Cochrane Risk of Bias Tool 2. A bayesian network meta-analysis using the “BUGSnet” package in R using a random-effects model with relative risk (RR) and 95% credible intervals (CrI) was conducted. A sensitivity analysis excluded studies in comorbid populations, those with a high risk of bias, and those without counselling to obtain more coherent and generalisable estimates for healthy adult smokers.

Result

Twenty-nine randomised controlled trials (RCTs) were included. All varenicline dosing strategies were effective at the end of their respective treatment periods. However, 12 weeks of 1 mg twice-daily (BID) was most certain to be effective for smokers with comorbidity (RR: 1.79; 95% CrI: 1.49 – 2.11) at 52 weeks follow-up. In the sensitivity analysis with comorbidity excluded, 52 weeks of 1 mg BID for healthy adult smokers maintained statistically significant efficacy at 52 weeks follow-up and ranked as the most effective dose (RR: 4.93; 95% CrI: 1.91-10.97). There were no statistically significant differences in safety between the varenicline doses.

Conclusion

The most effective and safe varenicline monotherapy dosing strategy was 52 weeks of 1 mg BID for healthy adult smokers and 12 weeks of 1 mg BID for smokers with comorbidity. Further RCTs are needed to strengthen the evidence for the 52-week of 1mg BID regimen, and RCTs conducted in comorbid populations to strengthen generalisability and support potential updates to current clinical guidelines.

Zitieren

APA

Nababan, S. P., Uirianto, G. N., Wira, J. F., Tenaya, W. J., & Anwar, D. F. F. (2026). Comparing the Efficacy and Safety of Different Varenicline Dosing Strategies for First-Line Cigarette Smoking Cessation: A Network Meta-Analysis. Journal of Asian Medical Students' Association. https://doi.org/10.52629/jamsa.vi.869

Vancouver

Nababan SP, Uirianto GN, Wira JF, Tenaya WJ, Anwar DFF. Comparing the Efficacy and Safety of Different Varenicline Dosing Strategies for First-Line Cigarette Smoking Cessation: A Network Meta-Analysis. Journal of Asian Medical Students' Association. 2026. doi:10.52629/jamsa.vi.869

BibTeX
@article{Nababan2026,
  author = {Nababan, Samuel Partogi and Uirianto, Gresita Novelia and Wira, Juan Fransiscus and Tenaya, Whitney Joycelyn and Anwar, Deva Fitra Firdausa},
  title = {Comparing the Efficacy and Safety of Different Varenicline Dosing Strategies for First-Line Cigarette Smoking Cessation: A Network Meta-Analysis},
  journal = {Journal of Asian Medical Students' Association},
  year = {2026},
  doi = {10.52629/jamsa.vi.869}
}
Kostenlos starten →